ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H. Wei; Harry J Iland; John Reynolds; Sun Loo; Chong Chyn Chua; David Alan Westerman; Ing Soo Tiong; Adam Ivey; Piers Blombery; Natasha S. Anstee; Rachel Koldej; David J. Curtis; David Andrew Kipp; David S. Ritchie; David Morrall Ross; Amanda Souza; Jenny Collins; Ashish Bajel; Carolyn S. Grove; Paula Marlton; Andrew W. Roberts; Naveen Pemmaraju; Keyur P. Patel; Sanam Loghavi; Marina Konopleva; Naval Daver; Courtney  DiNardo

doi:10.1182/blood-2022-167837

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H. Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Alan Westerman, Ing Soo Tiong, Adam Ivey, Piers Blombery, Natasha S. Anstee, Rachel Koldej, David J. Curtis, David Andrew Kipp, David S. Ritchie, David Morrall Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn S. Grove, Paula MarltonAndrew W. Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney DiNardo

Australian Centre for Blood Diseases

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	3341-3343
Number of pages	3
Journal	Blood
Volume	140
Issue number	Suppl 1
DOIs	https://doi.org/10.1182/blood-2022-167837
Publication status	Published - 15 Nov 2022
Event	Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022 - New Orleans, United States of America Duration: 10 Dec 2022 → 13 Dec 2022 Conference number: 64th https://www.sciencedirect.com/journal/blood/vol/140/suppl/S1 (Meeting abstract published in Supplementary Issue of Blood) https://www.hematology.org/meetings/annual-meeting

Access to Document

10.1182/blood-2022-167837

Cite this

Wei, A. H., Iland, H. J., Reynolds, J., Loo, S., Chua, C. C., Westerman, D. A., Tiong, I. S., Ivey, A., Blombery, P., Anstee, N. S., Koldej, R., Curtis, D. J., Kipp, D. A., Ritchie, D. S., Ross, D. M., Souza, A., Collins, J., Bajel, A., Grove, C. S., ... DiNardo, C. (2022). ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial. Blood, 140(Suppl 1), 3341-3343. https://doi.org/10.1182/blood-2022-167837

@article{1b3ae72ff1ec4a9db928d6f37f019a85,

title = "ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial",

author = "Wei, {Andrew H.} and Iland, {Harry J} and John Reynolds and Sun Loo and Chua, {Chong Chyn} and Westerman, {David Alan} and Tiong, {Ing Soo} and Adam Ivey and Piers Blombery and Anstee, {Natasha S.} and Rachel Koldej and Curtis, {David J.} and Kipp, {David Andrew} and Ritchie, {David S.} and Ross, {David Morrall} and Amanda Souza and Jenny Collins and Ashish Bajel and Grove, {Carolyn S.} and Paula Marlton and Roberts, {Andrew W.} and Naveen Pemmaraju and Patel, {Keyur P.} and Sanam Loghavi and Marina Konopleva and Naval Daver and Courtney DiNardo",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-167837",

language = "English",

volume = "140",

pages = "3341--3343",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Suppl 1",

note = "Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022, ASH 2022 ; Conference date: 10-12-2022 Through 13-12-2022",

url = "https://www.sciencedirect.com/journal/blood/vol/140/suppl/S1, https://www.hematology.org/meetings/annual-meeting",

}

Wei, AH, Iland, HJ, Reynolds, J, Loo, S, Chua, CC, Westerman, DA, Tiong, IS, Ivey, A, Blombery, P, Anstee, NS, Koldej, R, Curtis, DJ, Kipp, DA, Ritchie, DS, Ross, DM, Souza, A, Collins, J, Bajel, A, Grove, CS, Marlton, P, Roberts, AW, Pemmaraju, N, Patel, KP, Loghavi, S, Konopleva, M, Daver, N & DiNardo, C 2022, 'ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial', Blood, vol. 140, no. Suppl 1, pp. 3341-3343. https://doi.org/10.1182/blood-2022-167837

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial. / Wei, Andrew H.; Iland, Harry J; Reynolds, John et al.
In: Blood, Vol. 140, No. Suppl 1, 15.11.2022, p. 3341-3343.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT)

T2 - Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022

AU - Wei, Andrew H.

AU - Iland, Harry J

AU - Reynolds, John

AU - Loo, Sun

AU - Chua, Chong Chyn

AU - Westerman, David Alan

AU - Tiong, Ing Soo

AU - Ivey, Adam

AU - Blombery, Piers

AU - Anstee, Natasha S.

AU - Koldej, Rachel

AU - Curtis, David J.

AU - Kipp, David Andrew

AU - Ritchie, David S.

AU - Ross, David Morrall

AU - Souza, Amanda

AU - Collins, Jenny

AU - Bajel, Ashish

AU - Grove, Carolyn S.

AU - Marlton, Paula

AU - Roberts, Andrew W.

AU - Pemmaraju, Naveen

AU - Patel, Keyur P.

AU - Loghavi, Sanam

AU - Konopleva, Marina

AU - Daver, Naval

AU - DiNardo, Courtney

N1 - Conference code: 64th

PY - 2022/11/15

Y1 - 2022/11/15

U2 - 10.1182/blood-2022-167837

DO - 10.1182/blood-2022-167837

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 3341

EP - 3343

JO - Blood

JF - Blood

IS - Suppl 1

Y2 - 10 December 2022 through 13 December 2022

ER -